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Background: Hepatocellular carcinoma (HCC) patients with active hepatocyte growth factor (HGF)/c-Met signaling
have a significantly worse prognosis. c-Met, a high affinity receptor for HGF, plays a critical role in cancer growth,
invasion and metastasis. c-Met and CD44 have been utilized as cell surface markers to identify mesenchymal tumor-
initiating stem-like cells (TISC) in several cancers including HCC. In this work, we examine the complex relationship
between c-Met and CD44s (standard form), and investigate the specific role of CD44s as a tumor initiator and
stemness marker in HCC.
Methods: Gene and protein expression assays were utilized to investigate the relationship between CD44s and
c-Met in HCC cell lines. Tumor-sphere assays and in vivo tumor assays were performed to investigate the role of
CD44+ cells as TISCs. Student’s t-test or one-way ANOVA with Tukeys post-hoc test was performed to test for
differences amongst groups with a p < .05 as significant.
Results: In an immunohistochemical and immunoblot analysis of human HCC samples, we observed that more
than 39% of human HCC samples express c-Met and CD44. To study the relationship between c-Met and CD44,
we used MHCC97-H cells, which are CD44+/c-Met+. The knockdown of c-Met in MHCC97-H cells decreased
CD44s, reduced TISC characteristics and decreased tumorsphere formation. Furthermore, we demonstrate that the
inhibition of PI3K/AKT signaling decreased CD44s expression and subsequently decreased tumorsphere formation.
The down-regulation of CD44s leads to a significant loss of a TISC and mesenchymal phenotype. Finally, the down-
regulation of CD44s in MHCC97-H cells decreased tumor initiation in vivo compared with the scrambled control.
Conclusions: In summary, our data suggest that CD44s is modulated by the c-Met-PI3K-AKT signaling cascade to
support a mesenchymal and TISC phenotype in HCC cells. Moreover, c-Met could be a potential therapeutic drug
for targeting HCC cells with TISC and mesenchymal phenotypes.Background
Hepatocellular carcinoma (HCC) is the third leading
cause of cancer related deaths worldwide [1]. Evidence
suggests that HCC arises as a direct consequence of dys-
regulated proliferation of hepatic progenitor cells [2,3].
Such progenitors, called tumor-initiating stem-like cells
(TISCs), have been described in many different malignan-
cies, including HCC, and may account for poor survival
and chemotherapy resistance within specific tumors [4,5].
Transcriptome analysis of HCC has demonstrated that a
progenitor-based (TISC-phenotype) expression profile is* Correspondence: danghi@mail.nih.gov; carl_rountree@bshsi.org
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unless otherwise stated.associated with a poor prognosis compared with differen-
tiated tumors (hepatocyte-phenotype) [6-8]. TISCs exhibit
the capacity for rapid tumorsphere formation, enriched
stem cell gene expression profile, and efficient tumor
initiation in vivo. Moreover, recent evidence suggests
that TISCs have mesenchymal features such as low ex-
pression of E-cadherin and high expression of Fibronectin
and Zeb1 [9]. Furthermore, TISCs share multiple gene
networks involved in self-renewal (i.e. increased expres-
sion of stem cell markers such as NANOG, POU5F1
and BMI-1), drug efflux or resistance to chemotherapy
drugs, survival, and pluripotency with embryonic stem
cells [9,10].
c-Met is a receptor tyrosine kinase that, upon activation
by its ligand hepatocyte growth factor (HGF), promotes
malignant progression and metastasis in multiple cancers,his is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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are c-Met+, and c-Met expression is associated with a
poor prognosis [11,13,14]. Aberrant c-Met activation can
occur through multiple mechanisms, including autocrine
or paracrine ligand-dependent stimulation, mutational ac-
tivation or gene amplification [12]. During development,
homozygous deletion of HGF or c-Met is embryonic lethal
[15,16]. Although HGF/c-Met signaling does not play a
role in liver homeostasis during normal physiologic condi-
tions, many studies have demonstrated the important
role of HGF in liver regeneration, hepatocyte survival,
and tissue remodeling after acute injury. Following c-Met
phosphorylation and activation, multiple signaling path-
ways are involved as downstream targets, such as the
PI3K/AKT and MAPK/ERK1/2 pathways [17,18].
CD44 is a transmembrane cell adhesion glycoprotein
that participates in many cellular processes, including
the regulation of cellular growth, survival, differentiation,
lymphocyte homing, and motility [19,20]. The variety of
cellular processes affected by CD44 is likely the result of
multiple CD44 isoforms produced by alternative splicing
[21-23]. CD44s, the smallest (standard) form of CD44
(CD44s) is approximately 80–95 kD and lacks all CD44
variable exons. In breast cancer, cells undergoing EMT
exhibit increased CD44 expression and TISC character-
istics [24,25]. Although, CD44 expression has been de-
scribed within TISC populations, the isoform responsible
for the TISC characteristics remain unclear [20]. CD44s
is the predominant CD44 variant, which is ubiquitously
expressed in epithelial tissues, and has recently been pro-
posed to be essential for epithelial-to-mesenchymal transi-
tion (EMT) [26]. Recent studies demonstrate that the RNA
binding protein IMP3 stabilizes CD44 mRNA to facilitate
cell migration and more importantly, CD44s combined
with IMP3 can serve as a biomarker in predicting HCC
[27]. Together, these studies suggest the important role
of CD44s in HCC progression.
CD44+/c-Met+ cells have been demonstrated to be
tumorigenic with stemness characteristics in pancreatic
cancer, which suggests a dual role of c-Met and CD44
as regulators of tumor initiation [28]. More recently,
c-Met + inhibitors have been demonstrated to improve
overall survival of advanced HCC patients [12]. Thus,
understanding how c-Met elicits its oncogenic activities
is important in the development of HCC therapies.
Using HCC cell lines, we have previously demonstrated
that pharmacologic inhibition of c-Met results in the
decreased expression of CD44, which indicates a potential
link between CD44s and c-Met activation [11]. In the
current study, we investigate the co-regulation of c-Met
and CD44s. Here, we define a specific functional role of
CD44s as a tumor-initiating regulator in HCC. Our results
demonstrate that c-Met regulates tumor initiation and
mesenchymal stemness features through the activation ofPI3K/AKT/CD44s cascade. Our study provides insight on
how c-Met +HCC may be resistant to standard chemo-
therapy, implicating the importance of precision medicine
to improve overall survival in HCC patients.Methods
Cell culture
The human HCC cell line MHCC97-H was provided by
Dr. Xinwei Wang, from the National Cancer Institute
(NCI), under agreement with the Liver Cancer Institute,
Zhongshan Hospital, Fudan University, Shanghai, China,
and was cultured as previously described [11,29]. The hu-
man HCC cell lines Huh7 and Hep3B [acquired from
AddexBio (San Diego, CA)] were maintained as previously
described [30]. The human SK-Hep1 cells were provided
by Dr. Brian Barth, Penn State College of Medicine, and
maintained in Dulbecco’s modified Eagles Medium 1X
supplemented with 10% defined FBS (Hyclone Laboratories,
Logan, UT), 1 mM GlutaMAX-1 (Life Technologies),
100 U/ml penicillin and 100 μg/ml streptomycin. The
cells were cultured in a humidified incubator with 5%
CO2 at 37°C.siRNA and shRNA plasmid constructs and generation of
stable cell lines
c-Met siRNA was acquired from Thermo Scientific
(Dharmacon, Chicago, IL). Stable shRNA: TG320418
HuSH 29mer shRNA constructs against c-Met in the
pGFP-V-RS vector was purchase from OriGene (Rockville,
MD). The following constructs have been validated using
real-time PCR assays and have been used for developing
stable c-Met knock-down cell line. The c-Met shRNA
targeting sequence of construct 1: 5′-TACTGCTGAC
ATACAGTCGGAGGTTCACT-3′ and construct 2: 5′-
ACACTCCTCATTTGGATAGGCTTGTAAGT-3′. The
scrambled shRNA construct with the pGFP-V-RS back-
bone was purchased from OriGene (Cat# TR30013). Short-
hairpin construct oligonucleotide inserts of CD44s were
generated for the psiRNA-h7SK G1 (clone sites: Bbsl/Bbsl)
expression vector. Sequencing was performed to verify
the presence of the siRNA. The CD44s shRNA target-
ing construct was 5′-CAAGTGGACTCAACGGAGA-3′.
MHCC97-H cells were transfected with either scrambled
shRNA, c-Met shRNA, or CD44s shRNA using Fugene 6
transfection reagents per manufactures recommendation
(Promega, Sunnyvale, CA). Twenty-four hours after trans-
fection, puromycin (2 μg/ml) was added to select stable
c-Met shRNA clones, and 100 μg/ml of zeocin was added
to select stable CD44s clones. Multiple pooled clones of
stable MHHCC97-H cells containing scrambled shRNA
and CD44s shRNA and single clones containing c-Met
shRNA were isolated and expanded. Knock-down of
c-Met and CD44s expression was validated using both
Dang et al. BMC Cancer  (2015) 15:161 Page 3 of 11real-time PCR and western blot assays as previously
described [31,32].
qRT-PCR
RNA isolation and quantitative polymerase chain reaction
experiments were performed as previously described [24].
Western blot analysis
c-Met, phospho-c-Met (1349), phospho-c-Met (1234/1235),
AKT, phospho-AKT, ERK1/ERK2, phospho-ERK1/ERK2,
CD44, E-cadherin, vimetin, and moesin antibodies were
purchased from Cell Signaling Technology (Danvers, MA).
β-actin antibody was obtained from Sigma (Allentown, PA).
CD44v6 was obtained from eBioscience (San Diego, CA)
and fibronectin was obtained from BD Sciences (San Jose,
CA). All human HCC samples were obtained through an
IRB approved protocol (IRB#27146). Tissue samples were
incubated with lysis buffer and incubated on ice for 10 min
followed by disruption by the TissueLyser (Qiagen, CA) per
manufacturer’s recommendation. 15-30 μg of cell lysates
were collected and western blot was performed as previ-
ously described [30]. For densitometry analysis, scanned
blots were analyzed using Image J (v1.48. NIH, Bethesda,
MD) and normalized to Beta-Actin loading control after
background subtraction.
Microarray analysis
Using the MHCC97-H CD44s shRNA, MHCC97-H c-Met
shRNA or MHCC97-H scrambled shRNA cells, mRNA
was hybridized to an Illumina human gene chip as pre-
viously described by the Penn State Functional genom-
ics core [33]. Experiments were performed in triplicates.
Housekeeping genes were used as standards to generate
expression levels, and data analysis was conducted using
1.4-fold or greater change in expression with P < 0.05 as
significant. The full complement of the expression data
is available at http://www.ncbi.nlm.nih.gov/geo (accession
number GSE38343).
Spheroid formation assay/cell viability assays
The capability of self-renewal and cell viability assays were
assessed as previously described [24]. Briefly, 1X105
MHCC97-H cells were transfected with 25pM of c-Met
siRNA or scrambled siRNA (Thermo Scientific, Dharmacon,
Chicago, IL) followed by transfection of pBabe CD44s
construct or pBabe EV and incubated for an additional
24 hours. The cells were counted with trypan blue ex-
clusion and 5x103 cells were plated onto low adherent
6-well plates for an additional 2 weeks.
Animal care and xenograft transplantation experiments
Nude Mice (Jackson Laboratory, Bar Harbor, ME) were
fed and housed as previously described [11]. All of the
procedures were in compliance with our institution’sguidelines for the use of laboratory animals and approved
by the Penn State Institutional Animal Care and Use
Ethics Committee. The cells were counted with trypan
blue exclusion and suspended in a 1:3 dilution of Matrigel
(Matrigel: DMEM/F12 supplemented with 10% FBS).
Three different cell dilutions were used for bilateral subcuta-
neous injection: 1X104 cells/100 mL, 1X103 cells/100 mL
and 1X102 cells/100 mL. Serial diluted cells were inoculated
into 10-week-old female nude mice (Jackson Laboratory,
Bar Harbor, ME). Tumor initiation was checked every 3–4
days after injection. Caliper measurements of tumor volume
(length ×width × height) were conducted at the end of the
study. The mice were sacrificed, and tumor tissues were
fixed for histology studies or frozen for protein extraction.
Statistical analysis
Microarray statistical analysis was performed as describe
[33]. Student’s t test was used comparing two groups.
One-way ANOVA was used when comparing multiple
groups followed by Tukeys post-hoc test to look for dif-
ferences amongst groups. All analysis with a p < 0.05 was
considered statistically significant.
Immunohistochemistry
Paraffin embedded slides were labeled with anti-CD44
(Cell Signaling, Danvers, MA) and anti-c-Met antibodies
(Cell Signaling) and stained as previously described [11].
Slides were scored positive if CD44 or c-Met staining
were >10% positive for each sample. HD and SS scored
all IHC samples. Only samples that were considered posi-
tive by both HD and SS were used for statistics.
Flow cytometry (FACS) analysis
FACS experiments were performed using one million
cells, incubated with mouse anti-human CD44-PE (BD
Biosciences, Falcon Lakes, NJ) or anti-human c-Met/2-APC
(eBiosciences, San Diego, CA). Analysis was performed
using a FACS Calibur (BD Biosciences, Falcon Lakes,
NJ). Post-FACS analysis was performed using the Flow-Jo
program (Tree Star, Ashland, OR). Positive and negative
gates were determined using immunoglobulin G (IgG)-
stained and unstained controls.
Results
CD44 expression correlates with c-Met expression in hu-
man HCC
To investigate the correlation between c-Met and CD44,
we performed immunohistochemistry staining on 68 HCC
tumors (Figure 1B) and immnoblotted 33 HCC tumors
(Figure 1A). Immunohistochemical analysis demonstrated
that 39% (27/68) of the human HCC samples are c-Met+
CD44+ (Figure 1B). Immunoblot analysis of an add-










Figure 1 CD44s correlates with c-Met expression in human HCC
samples. (A) Representative western blot in which 7 out of 33 human
clinical HCC samples demonstrating c-Met, CD44v6 and CD44s
co-expression. See Additional file 1: Figure S1 for all 33 samples.
(B) Representative images of CD44 and c-Met immunohistochemistry
performed on 68 human HCC tissues using anti-CD44 and c-Met
antibodies (400X).
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(Figure 1A and Additional file 1: Figure S1).
c-Met+CD44s+ HCC cells have increased mesenchymal
characteristics
To study the potential relationship between CD44s and
c-Met in HCC, we characterized four human HCC cell
lines: Huh7, Hep3B, Sk-Hep1 and MHCC97-H. Flow cy-
tometry analysis demonstrates that both the SK-Hep1
and MHCC97-H cell lines are 99% CD44+ compared
with the Huh7 and Hep3B cells, whose CD44+ cell pro-
portions are less than 1.5% (Additional file 2: Figure S2A).
Further characterization of the four cell lines demonstrate
that CD44+ cell lines can readily form tumorspheres,
have a mesenchymal phenotype with decreased E-cadherin,
and have resistance to sorafenib and doxorubicin chemo-
therapy treatment (Figure 2A-D) and Additional file 2:Figures S2B-C). The MHCC97-H cells demonstrated
increased expression of both CD44 and c-Met; thus, the
MHCC97-H cells provide the best model for the c-
Met+/CD44+ HCC phenotype that has been observed
in human HCC samples.
c-Met regulates TISC characteristics, mesenchymal
features, and CD44s expression
We have previously demonstrated that pharmacologic
inhibition of c-Met in MHCC97-H cells results in a re-
duction of tumor growth and decreased CD44 expres-
sion [11]. Moreover, previous studies have demonstrated
that CD44v6 interacts with c-Met to enhance downstream
MET activation. Therefore, we wanted to test whether
CD44v6 was modulated by c-Met inhibition. Interestingly,
inhibition of c-Met by PHA66572, a selective inhibitor
of c-Met, had a greater effect on CD44s (approxi-
mately 85-95kDA) than CD44v6 (approximately 160kDA)
(Figure 3A).
To test how c-Met regulates CD44s, we individually
targeted PI3K/AKT or MAPK/ERK1/2 pathways using
the small molecule inhibitors LY294002 and PD798059,
respectively. CD44s expression was significantly decreased
after PI3K inhibition (LY29402) compared with vehicle
(DMSO) control but only a slight change with MAPK in-
hibition (PD798059, Figure 3B). This suggests that CD44s
expression is regulated by the c-Met-PI3K-AKT signaling.
To further investigate the relationship between c-Met
and CD44s, we developed a stable MHCC97-H c-Met
shRNA cell line (Figure 3C). In the MHCC97-H c-Met
shRNA cells, PI3K/AKT, MAPK/ERK1/2 signaling, and
CD44s expression are down-regulated compared to con-
trol cells. Furthermore, the down-regulation of c-Met leads
to increased E-cadherin expression, decrease Fibronec-
tin expression and decreased tumorsphere formation
(Figure 3C and D).
CD44s regulates TISC and mesenchymal characteristics
We next wanted to test whether the regulation of
TISC and mesenchymal features is through CD44s. To
do so, MHCC97-H cells were treated with LY294002
or PD798059 for two weeks in low adherent culture
conditions. Accordingly, LY294002 was able to signifi-
cantly inhibit tumorsphere formation compared to vehicle
or PD98059 (Figure 4A), suggesting that the inhibition of
PI3K activity and subsequent loss of CD44s could inhibit
tumorsphere formation.
The down-regulation of CD44s and the significant de-
crease in tumorsphere formation after PI3K/AKT inhib-
ition suggests that CD44s may be a critical TISC regulator.
To test whether CD44s regulates tumor-initiating charac-
teristics, we generated stable MHCC97-H CD44s shRNA
cell lines (Figure 4B) and performed microarray analysis.
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Figure 2 CD44s+ HCC cells have mesenchymal and tumor-initiating stem-like characteristics. (A) Protein expression of endogenous CD44s,
c-Met, and mesenchymal markers. The data are representative of three independent experiments. (B) Relative mRNA expression of mRNAs encoding
CD44, E-cadherin and c-Met normalized to the endogenous control GAPDH. Data represent mean ± SEM of triplicates, *p < 0.01. (C) Tumorsphere assay
was performed for two weeks in non-adherent culture plates and the numbers of tumorspheres were counted. The data represent the mean ± SEM of
triplicates, *p < 0.01. Phase-contrast images are representative of triplicates (40X magnification). (D) HCC cells were treated with sorafenib for
24 h. Endogenous protein expression of apoptotic markers PARP, cleaved PARP, and B-actin were measured via western blotting. Presented
densitometry values represent relative expression relative to total PARP after normalization to B-actin.
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mesenchymal, and TISC markers and increased epithelial
markers (Figure 4C). Moreover, qRT-PCR analysis con-
firmed the significant down-regulation of TISC genes
(Figure 4D).
c-Met activation of mesenchymal and TISC characteristics
occurs through CD44s
Our observations thus far suggest that c-Met regulates
CD44s expression through PI3K-AKT signaling to mediate
mesenchymal and TISC characteristics. To further investi-
gate the role of CD44s in regulating TISC characteristics,
we compared MHCC97-H monolayer cultured cells with
tumorspheres. Accordingly, immunoblot analysis shows
no difference in c-Met expression and a significant in-
crease in CD44s expression in tumorspheres compared
with monolayer cells (Figure 5A). This data support ourobservations that CD44s is important for tumorsphere
formation, one important characteristic of TISCs.
To further confirm that CD44s is required for tumor-
sphere formation downstream of c-Met, we performed a
tumorsphere assay with MHCC97-H scrambled, c-Met
and CD44s shRNA stable cell lines. The down-regulation
of CD44s significantly decreased tumorsphere formation
compared with c-Met or scrambled shRNA (Figure 5B).
Next we tested the hypothesis that CD44s can rescue
tumorsphere formation after c-Met inhibition. To test
our hypothesis, MHCC97-H cells were transfected with
c-Met or scrambled siRNA followed by the over-expression
of CD44s for 48 hrs. As previously demonstrated, the
down-regulation of c-Met decreased CD44s and Fibro-
nection and increased E-cadherin expression (Figure 5C).
However, followed by the subsequent over-expression of
CD44s, there was an increase in Fibronectin expression.
A B DMSO+ - -
- - +













































Figure 3 c-Met regulates CD44s expression through AKT signaling. (A) MHCC97-H cells were treated with 1 μM of PHA665752 for 24 h.
Immunoblot analysis of CD44v6 (~160 kDa), CD44s (~85 kDa), and B-actin. (B) MHCC97-H cells were treated with 25 μM DMSO, LY294002
(PI3K inhibitor) or PD98059 (MEK inhibitor) for 24 h, and immunoblot analysis was performed. (C) MHCC97-H cells were stably transfected
with c-Met shRNA. Lysates were collected after 2 passages and CD44s, fibronectin, and E-cadherin expression was via immunoblotting. (D)
Tumorsphere formation (40X magnification) assay of stably transfected MHCC97-H cells with c-Met shRNA compared to scrambled control.
The data represent the mean ± SEM of triplicates, *p < 0.01. Phase-contrast images are representative of triplicates (40X magnification).
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tumorsphere formation (Figure 5D). Together, our data
suggest that c-Met regulates TISC and mesenchymal fea-
tures through CD44s via the PI3K-AKT signaling cascade.
CD44s regulates tumor initiation in vivo
To test whether CD44s regulates tumor initiation in vivo,
we subcutaneously injected athymic nude mice with 1 ×
102, 1 × 103, or 1 × 104 MHCC97-H CD44s or scrambled
shRNA cells (Figure 6A). Tumor incidence was observed
and tumor volume measured at the end of the experiment.
Accordingly, the down-regulation of CD44s results in the
inhibition of tumor initiation and growth in lower cell
dilutions compared to scrambled shRNA controls
(Figure 6B-D), an important TISC characteristic.
Discussion
Hepatocellular carcinoma (HCC), the fifth most common
cancer in men and seventh in women, is on the rise in theUnited States [34]. Due to the diverse etiologies of HCC,
including hepatitis B virus (HBV) and hepatitis C virus
(HCV) infection, alcoholic diseases and obesity, and its
direct impact on the heterogeneity of the tumor, there
are limited treatment options with poor survival [35].
Sorafenib is the only FDA approved therapy for advanced
HCC, however the benefits are modest [36]. In a ran-
domized clinical trials phase II study, tivantinib, a c-Met
inhibitor, has demonstrated to be a promising antitumor
agent in c-Met high patients with a median overall sur-
vival of more than seven months [37,38]. Notably, we have
previously demonstrated that the inhibition of c-Met in
c-Met + HCC significantly reduces tumor burden [11].
Together, these studies support the idea that targeted
therapy is important for improving the overall survival
of HCC patients.
HCC patients with an active c-Met signaling or TISC
transcriptome profile have a poor prognosis. In solid tu-















































Figure 4 CD44s regulates mesenchymal and tumor-initiating stem-like characteristics. (A) Tumorsphere assay of MHCC97-H cells treated
with DMSO, LY294002 or PD98059 (25 μM) for 24 h followed by trypan blue exclusion. 1x10^5 cells were plated in triplicates in 6-well low adherent
plates for an additional 2 weeks. The data represent the mean ± SEM of triplicates, *p < 0.05. Phase contrast images are at 40X magnification.
(B) Endogenous protein levels of CD44s and the mesenchymal markers E-cadherin and Fibronectin in two pooled stable CD44s shRNA cell
lines. (C-D) Heatmap of MHCC97-H CD44s shRNA compared to scrambled control cells. Relative mRNA expression of stem cell genes in CD44s
shRNA #1 compared with the scrambled control normalized to GAPDH. The data represent the mean ± SEM of triplicates, *p < 0.001.
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and efficient tumor initiation in limited dilution studies
[5,28,39-42]. In this study, we demonstrate the underlying
mechanism of how c-Met elicits its tumorigenic properties
through the activation of CD44s to induce a mesenchymal
and TISC phenotype. Although the importance of CD44 in
tumor progression and TISC populations has been demon-
strated, most reports that define TISC populations with
CD44 utilize antibodies that recognizes all CD44 isoforms
[20]. However, which CD44 variants are responsible for the
TISC phenotypes has yet to be elucidated. In this study, we
demonstrate the underlying mechanism of how c-Met
elicits its tumorigenic properties through the activation of
CD44s in order to induce a mesenchymal and TISC pheno-
type. Our findings establish for the first time the functional
relationship between the CD44 standard variant (CD44s)
and c-Met in regulating a TISC phenotype. We confirm
that CD44s and c-Met are co-expressed in human HCC by
using our own data set [8,43]. We discovered a novel regu-
latory relationship between CD44s and c-Met that controlsmesenchymal and TISC phenotype through the PI3K-AKT
signaling pathway.
The relationship between c-Met and CD44v6 is well
established [44-46]. Specifically, c-Met regulates CD44 al-
ternative splicing to promote CD44v6 production through
RAS signaling [47]. In turn, CD44v6 interacts with c-Met
by presenting HGF and subsequently sustains RAS signal-
ing to promote cell proliferation [44,45,47]. This positive
feedback loop occurs in an HGF-dependent manner. In
the MHCC97-H cells both CD44v6 and CD44s isoforms
are expressed. In our work, the down-regulation of c-Met
leads to a slight change in CD44v6 expression, suggesting
that c-Met may also regulate CD44v6. The question arose
as to why cancer cells would express both CD44s and
CD44v6 isoforms. This different role of CD44 on c-Met is
explained by the difference in CD44 isoforms involved
[20]. While CD44v6 amplifies c-Met signaling and cell
proliferative through RAS signaling as described by others,
our data suggest that c-Met regulates CD44s to promote a
mesenchymal and TISC phenotype via the PI3K cascade.
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Figure 5 c-Met induces tumor-initiating characteristics through CD44s. (A) 5x104 MHCC97-H cells were plated onto 6-well low adherent
culture plates in triplicates. Tumorspheres were collected by centrifugation after 2 weeks . For monolayer cultured cells, 5x104 MHCC97-H were
plated on 10 cm plate and cultured for 2 weeks. Media was changed every 2–3 days. MHCC97-H cells were plated in low-adherent cell or monolayer cell
culture dishes for two weeks and immunoblotting analysis was confirmed on tumorsphere lysates. The data are representative of three independent
experiments. (B) 5x103 MHCC97-H scrambled, c-Met shRNA and CD44s shRNA cells were grown in 6-well low-adherent culture plates for two weeks and
the numbers of tumorspheres were counted (40X magnification). The data are representative of two independent experiments and are shown as the
mean ± SEM of triplicate plates. (C) CD44s recovers tumorsphere formation. MHCC97-H cells were transfected with c-Met siRNA (25pM) for
24 hrs followed by overexpression of CD44s or pBabe empty vector retrovirus for an additional 48 h (immunoblot) or two weeks (tumorsphere assay).
(D) Immunoblot data are representative of two independent experiments. The data for the tumorsphere assay data are representative of two
independent experiments and are shown as the mean ± SEM of triplicate wells (40X magnification).
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TISC phenotype, it has been demonstrated that CD44v6 is
important for cell migration and metastasis by promoting
c-Met signaling through ERM (ezrin, radaxin, and moesin)
proteins [21,45,48]. By expressing both CD44 isoforms in
c-Met + tumors, cancer cells are more likely to be resistant
to standard treatment, metastasize, and colonize at distant
organ sites. Thus, our current study supports the idea
that combination therapy with c-Met inhibitor and CD44
monoclonal antibody may be more effective in anti-tumor
activity than c-met inhibition alone. Moreover, the CD44monoclonal antibody has been demonstrated to be effect-
ive in chronic lymphocytic leukemia [49]. Although the
role of CD44v6 in cell migration has been well studied in
other solid tumors, its functional role in HCC will need to
be further investigated.
In this work, we demonstrate the importance of the
c-Met/AKT/CD44s cascade in promoting a TISC pheno-
type. The down regulation of CD44s significantly decreased
tumorsphere formation compared with c-Met shRNA cells.
However, CD44s was not able to fully rescue tumorsphere












































































Figure 6 CD44s regulates tumor initiation in vivo. (A) Immunoblot of MHCC97-H scrambled and CD44s shRNA #1 before cells were injected
into athymic nude mice. (B-D) Tumor initiation graph of MHCC97-H CD44s shRNA compared with the scrambled shRNA control. Bilateral subcutaneous
injections of 1x102, 1x103, or 1x104 cells were inoculated into athymic nude mice, and the number of tumors formed and the percent tumor initiation
were calculated (1x102, N = 10; 1x103, N = 8; or 1x104, N = 6). Tumor volume was calculated at the end of the experiment and. Data represent
the mean ± SD. Confirmation of down-regulation of CD44s and c-Met signaling was performed by immunoblotting.
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CD44s. The c-Met/HGF signaling cascade is important
for morphogenesis during embryonic development and
organ regeneration by inducing EMT and can be high-
jacked by cancer cells to promote metastasis [12,50].
Furthermore, c-Met has been implicated in regulating the
stem/progenitor phenotype by transcriptional regulation
of stemness factors including NANOG, POU5F1, and
Sox2 [42]. Therefore, it is likely that c-Met, through othermechanisms independent of CD44s, can regulate the TISC
and mesenchymal phenotype.
Prior studies have demonstrated that the PI3K/AKT
signaling cascades promote a mesenchymal phenotype.
Studies have suggested that constitutive PI3K/AKT signal-
ing is required for EMT in squamous cell carcinoma,
whereas PI3K/AKT signaling is required for TGFβ in-
duced EMT in breast cancer cells [51,52]. Furthermore,
TGFβ-induced EMT generates CD44+/CD24− TISCs [25].
Dang et al. BMC Cancer  (2015) 15:161 Page 10 of 11Here, we provide evidence consistent with previous
findings that the PI3K/AKT signaling is a central pathway
for a mesenchymal phenotype through the c-Met/PI3K/
AKT/CD44s cascade.
Conclusions
In this study, we demonstrate a positive correlation be-
tween CD44s and c-Met in clinical HCC samples and
show, for the first time, a functional relationship between
CD44s and c-Met within HCC. We present evidence that
c-Met regulates CD44s to drive a mesenchymal and TISC
phenotype and that the down regulation of CD44s de-
creases tumor initiation both in vitro and in vivo. Our data
provide insight into how c-Met induces hepatocarcinogen-
esis and further support the idea that c-Met represents a
potential target for the treatment of c-Met + HCC.
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